Difference between revisions of "Irinotecan (Camptosar)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 7: Line 7:
  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref>  
 +
 +
==Diseases for which it is used==
 +
*[[Bone cancer]]
 +
*[[Central nervous system (CNS) cancer]]
 +
*[[Cervical cancer]]
 +
*[[Colon cancer]]
 +
*[[Esophageal cancer]]
 +
*[[Pancreatic cancer]]
 +
*[[Penile cancer]]
 +
*[[Small cell lung cancer]]
 +
*[[Unknown primary]]
  
 
==Patient drug information==
 
==Patient drug information==
Line 13: Line 24:
  
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
−
* 6/14/1996: Initial FDA approval
+
* 6/14/1996: Initial FDA approval for the treatment of patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed following [[Fluorouracil (5-FU) | 5-FU-based]] therapy.
 +
* 4/20/2000: Colon cancer indication revised:
 +
** Indicated as a component of first-line therapy in combination with [[Fluorouracil (5-FU) | 5-fluorouracil]] and [[Folinic acid (Leucovorin) | leucovorin]] for patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]].
 +
** Also indicated for patients with metastatic carcinoma of the [[Colon cancer | colon]] or [[Rectal cancer | rectum]] whose disease has recurred or progressed following initial [[Fluorouracil (5-FU) | fluorouracil-based]] therapy.
  
 
==Also known as==
 
==Also known as==
Line 48: Line 62:
 
<references/>
 
<references/>
  
 +
[[Category:Drug index]]
 
[[Category:Chemotherapy]]
 
[[Category:Chemotherapy]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Irritant chemotherapy]]
 
[[Category:Topoisomerase inhibitors]]
 
[[Category:Topoisomerase inhibitors]]
 +
 
[[Category:Bone cancer medications]]  
 
[[Category:Bone cancer medications]]  
 
[[Category:Cancer of unknown primary medications]]  
 
[[Category:Cancer of unknown primary medications]]  
Line 60: Line 76:
 
[[Category:Penile cancer medications]]  
 
[[Category:Penile cancer medications]]  
 
[[Category:Small cell lung cancer medications]]
 
[[Category:Small cell lung cancer medications]]
 +
 +
[[Category:Drugs FDA approved in 1996]]

Revision as of 15:03, 25 October 2014

General information

Class/mechanism: Topoisomerase I inhibitor; derivative of camptothecin, which interferes with topoisomerase I's normal action of relieving torsional strain in DNA by creating reversible single-strand breaks. Irinotecan and its active metabolite SN-38 bind to the topoisomerase I & DNA complex and interfere with ligation of these single-strand breaks. Failure to repair these breaks eventually leads to double-strand DNA damage, which disrupts cell proliferation and leads to cell death.[1][2]
Route: IV
Extravasation: irritant

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 6/14/1996: Initial FDA approval for the treatment of patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following 5-FU-based therapy.
  • 4/20/2000: Colon cancer indication revised:

Also known as

Synonyms
Campto Conc Camptosar Cloridrato DE Irinotecano CPT-11 Elinatecan
Faultenocan Irenax Irinogen Irinotecan Hydrochloride Irinotecan Mayne
Irinotecan Rovi Irinotel Irnocam Itoxaril Linatecan
Satigene Tecnotecan Topotecin Trinotecan Winol

References

  1. ↑ 1.0 1.1 Irinotecan (Camptosar) package insert
  2. ↑ Irinotecan (Camptosar) package insert (locally hosted backup)
  3. ↑ Irinotecan (Camptosar) patient drug information (Chemocare)
  4. ↑ Irinotecan (Camptosar) patient drug information (UpToDate)
Retrieved from "https://hemonc.org/w/index.php?title=Irinotecan_(Camptosar)&oldid=5180"